136th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2069601204641842 Karnataka164924842322998 Delhi1427231282324082 Uttar Pradesh113378668341981 West Bengal89666630601954 Telangana7525753239601 Bihar7179446294400 Gujarat68855517922604 Assam5549737225132 Rajasthan4941835186763 Odisha4255028698292 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3170019147103 Jammu and Kashmir2392716218449 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
Lifestyle Sex and Relationship 18 Apr 2019 Vaginal dryness and ...

Vaginal dryness and low sex drive post adjuvant endocrine therapy

ANI
Published Apr 18, 2019, 10:56 am IST
Updated Apr 18, 2019, 10:56 am IST
Relationship status influences sexual problems and self-efficacy in breast cancer survivors: Study.
Survivors of breast cancer, particularly those on aromatase inhibitors, often have unaddressed sexual concerns. (Photo: Representational/Pexels)
 Survivors of breast cancer, particularly those on aromatase inhibitors, often have unaddressed sexual concerns. (Photo: Representational/Pexels)

Washington: Vaginal dryness and painful intercourse are some of the common adverse events of post-breast cancer treatment therapies. These often lead to sexual dissatisfaction and lower quality of life (QOL) among breast cancer survivors. However, recent findings suggest that women who have partners may fare better than those without a partner. 

Breast cancer is the leading cancer diagnosis in women, with more than 266,000 new cases estimated in 2018. More than 70% of these cases occur in women aged older than 50 years. Adjuvant endocrine therapy (AET), such as tamoxifen, is often recommended for postmenopausal women for as long as 10 years after completion of breast cancer treatment as a means to limit the risk of cancer recurrence.

 

Unfortunately, AET has many adverse effects, including sexual problems in the form of vaginal dryness, painful intercourse, and low sexual desire. Previous studies have associated sexual problems with poor QOL, whereas others have shown that partnered survivors of breast cancer have better QOL than partnered survivors.

However, this new study examined how partner status influences the relationships between sexual problems and self-efficacy for managing sexual problems and QOL domains for postmenopausal survivors of breast cancer taking AET.

 

Its findings, published in the Journal of the North American Menopause Society suggest that unpartnered postmenopausal women with greater sexual problems or lower self-efficacy may be at a greater risk to experience decreased QOL than partnered women.

 “Survivors of breast cancer, particularly those on aromatase inhibitors, often have unaddressed sexual concerns, and healthcare providers aren't asking about them. In this study, postmenopausal, unpartnered women were the most vulnerable to having quality-of-life issues and also sense-of-self affected by unaddressed sexual problems,” said JoAnn Pinkerton, lead author of the study.

 

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT